

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



撥康視云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the “**Board**”) of directors (the “**Directors**”) of Cloudbreak Pharma Inc. (the “**Company**”) hereby announces that the principal place of business of the Company in Hong Kong has been changed to Suite 23A11, 23Ath Floor, Tower 2, The Gateway, Harbour City, Kowloon, Hong Kong.

The telephone and website of the Company remained unchanged.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI, Jinsong
Chairman, Executive Director and chief executive officer

Hong Kong, 26 August 2025

Directors of the Company named in the application to which this announcement relates are: (i) Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong as executive directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive directors; and (iii) Mr. Lai Hin Wing Henry Stephen, Mr. Liu Chung Mun and Ms. Nie Sijiang as independent non-executive directors.

* For identification purpose only